4.6 Article

Between-group differences in infra-patellar fat pad size and signal in symptomatic and radiographic progression of knee osteoarthritis vs non-progressive controls and healthy knees - data from the FNIH Biomarkers Consortium Study and the Osteoarthritis Initiative

期刊

OSTEOARTHRITIS AND CARTILAGE
卷 25, 期 7, 页码 1114-1121

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.joca.2017.02.789

关键词

Infra-patellar fat pad; Knee osteoarthritis; Progression; Knee pain; Healthy; Intermediate-weighted MRI

资金

  1. Foundation for the NIH (FNIH) Osteoarthritis (OA) Biomarkers Consortium
  2. AbbVie
  3. Amgen Inc.
  4. Arthritis Foundation
  5. Bioiberica SA
  6. DePuy Mitek, Inc.
  7. Flexion Therapeutics, Inc.
  8. GlaxoSmithKline
  9. Merck Serono
  10. Rottapharm j Madaus
  11. Sanofi
  12. Stryker
  13. Pivotal Osteoarthritis Initiative Magnetic Resonance Imaging Analyses (POMA) study (NIH/National Heart, Lung, and Blood Institute) [HHSN2682010000]
  14. NIH [N01-AR-2-2258, N01-AR-2-2259, N01-AR-2-2260, N01AR-2-2261, N01-AR-2-2262]
  15. Merck Research Laboratories
  16. Novartis Pharmaceuticals
  17. Pfizer, Inc.
  18. Paracelsus Medical University Research Fund [PMU-FFF E-14/99/099-RUH]

向作者/读者索取更多资源

Objective: To examine cross-sectional and longitudinal between-group differences of infra-patellar fat pad (IPFP) size and magnetic resonance imaging (MRI) signal from fat-suppressed intermediate-weighted images with clinically relevant symptomatic and radiographic progression of knee osteoarthritis (OA), vs healthy references. Methods: We studied 110 case knees (Kellgren-Lawrence Grade [KLG1-3]) with radiographic (>= 0.7 mm loss in joint space width [JSW]) and symptomatic progression (>= +9/100 units on the Western Ontario and McMasters Universities Osteoarthritis Index [WOMAC] knee pain subscale) vs 118 control knees without progression from the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium cohort. We further studied 88 knees from the Osteoarthritis Initiative (OAI) healthy reference cohort without (risk factors) of knee OA. The IPFP was manually segmented using baseline and year-2 sagittal fat-suppressed intermediate-weighted spin-echo 3 T MRIs. Baseline measures and longitudinal change in IPFP volume and 3D MRI signal (mean, standard deviation [SD]) were compared between groups. Results: No statistically significant baseline differences in IPFP volume, 3D MRI signal mean or signal heterogeneity (SD) were observed between progressor and non-progressor OA knees. Yet, the IPFP 3D MRI signal SD, but not its volume, was statistically significantly greater in OA vs healthy knees. No statistically significant 2-year changes in IPFP volume were observed in either group, but the increase in 3D MRI signal heterogeneity (SD) was greater in progressor vs non-progressor knees, and was greater in OA vs healthy knees. Conclusion: Whereas IPFP-related morphometric measures did not statistically significantly differ between groups, a stronger increase in 3D IPFP MRI signal and signal heterogeneity may be associated with radiographic/symptomatic progression of OA, when compared to non-progressive OA or healthy knees. (C) 2017 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据